ac0058ta
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02847325)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ac0058ta
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03878303 | Phase 1 | Nov 28, 2018 | Acea Bio, Metroplex Clinical Research |
| NCT02847325 | Phase 1 | May 1, 2016 | Acea Bio, Covance |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acea Bio | For profit | 2 | 2 | 1 | 2016 |
| Covance | For profit | 1 | 0 | 1 | 2016 |
| Metroplex Clinical Research | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1